BCEL Stock : Atreca, Inc., is a biopharmaceutical firm. It is a biopharmaceutical company that develops immunotherapies and therapeutics based upon a deep understanding the human immune system. The company’s technology uses next-generation sequencing to determine the functional antibodies that are produced by patients during an immune reaction. Robert Axtell and Guy Cavet founded the company, along with Tito A. Serafini and Jeremy Sokolove and Paulette A. Dillon. The company is based in San Carlos, CA.
BCEL Stock : Atreca Returns vs. S&P
| 1 Year | 5 YEARS | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| BCEL | -21.23% | -91% | ||
| S&P | -14.41% | +42.63% | +7.36% | +33% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $20.90M | -81.5% |
| Accounts Receivable | – | – |
| Inventory | 0 | – |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $61.25M | – |
| Short Term Debt | $3.43M | – |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -53.7% | +29.4% |
| Return On Invested Capital | -51.7% | +10.1% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$16.60M | -10.5% |
| Operating Free Cash Flow | -$16.36M | +1.9% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 0.64 | 0.77 | 0.50 | 0.53 | -54.6% |
| Price to Sales | 133.50 | 95.79 | 76.08 | 81.06 | -57.1% |
| Price to Tangible Book Value | 0.64 | 0.77 | 0.50 | 0.53 | -54.6% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | 0.12 | -2.97 | -1.25 | -1.85 | -37.9% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -55.1% | -60.4% | -69.9% | -77.5% | +64.7% |
| Total Debt | $0.00M | $66.27M | $65.49M | $64.69M |
